The O-linked glycans of human von Willebrand factor modulate its interaction with ADAMTS-13

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 1, 2014, Pages 54-61

  Nowak, A A ^a   Mckinnon, T A J ^a   Hughes, J M ^a   Chion, A C K ^a   Laffan, M A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ADAMTS13 protein human; Collagen; Glycosylation; Hemostasis; Proteolysis; Von Willebrand factor

Indexed keywords

COLLAGEN; GLYCAN; O LINKED GLYCAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SHEAR FLOW;

ADAMTS13 PROTEIN HUMAN; COLLAGEN; GLYCOSYLATION; HEMOSTASIS; PROTEOLYSIS; VON WILLEBRAND FACTOR;

ADAM PROTEINS; HEK293 CELLS; HUMANS; POLYSACCHARIDES; PROTEIN BINDING; PROTEOLYSIS; VON WILLEBRAND FACTOR;

EID: 84891898185     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12451     Document Type: Article

References (24)

1. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
2. Tsai HM. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura. Int J Hematol 2002; 76(Suppl. 2): 132-8.
3. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997; 89: 1954-62.
4. Hanisch FG. O-glycosylation of the mucin type. Biol Chem 2001; 382: 143-9.
5. Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, Laffan M, Dell A. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost 2010; 8: 137-45.
6. Hang HC, Bertozzi CR. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem 2005; 13: 5021-34.
7. Jentoft N. Why are proteins O-glycosylated? Trends Biochem Sci 1990; 15: 291-4.
8. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-84.
9. Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA. O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood 2012; 120: 214-22.
10. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008; 15: 3042-9.
11. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-93.
12. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280: 21773-8.
13. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111: 651-7.
14. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 2007; 5: 1363-70.
15. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, Deckmyn H. Shielding of the A1 domain by the D′D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 2006; 281: 4699-707.
16. McGrath RT, McKinnon TA, Byrne B, O'Kennedy R, Terraube V, McRae E, Preston RJ, Laffan MA, O'Donnell JS. Expression of terminal {alpha}2-6 linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010; 115: 2666-73.
17. Badirou I, Kurdi M, Legendre P, Rayes J, Bryckaert M, Casari C, Lenting PJ, Christophe OD, Denis CV. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS ONE 2012; 7: e37508.
18. Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. J Thromb Haemost 2012; 10: 940-50.
19. Coltart DM, Royyuru AK, Williams LJ, Glunz PW, Sames D, Kuduk SD, Schwarz JB, Chen XT, Danishefsky SJ, Live DH. Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. J Am Chem Soc 2002; 124: 9833-44.
20. Shogren R, Gerken TA, Jentoft N. Role of glycosylation on the conformation and chain dimensions of O-linked glycoproteins: light-scattering studies of ovine submaxillary mucin. Biochemistry 1989; 28: 5525-36.
21. Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996; 35: 7299-307.
22. Ying J, Ling Y, Westfield LA, Sadler JE, Shao JY. Unfolding the A2 domain of von Willebrand factor with the optical trap. Biophys J 2010; 98: 1685-93.
23. Hanisch FG, Muller S, Hassan H, Clausen H, Zachara N, Gooley AA, Paulsen H, Alving K, Peter-Katalinic J. Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-acetylgalactosamine:peptide N-acetylgalactosaminyltransferases. site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions. J Biol Chem 1999; 274: 9946-54.
24. Johnsen JM, Auer PL, Morrison AC, Jiao S, Wei P, Haessler J, Fox K, McGee SR, Smith JD, Carlson CS, Smith N, Boerwinkle E, Kooperberg C, Nickerson D, Rich SS, Green D, Peters U, Cushman M, Reiner AP. Common and rare von Willebrand factor (VWF) coding variants, von Willebrand factor levels, and factor VIII levels in African Americans. Blood 2013; 122: 590-7.